ROCKVILLE, Md., Feb. 25, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that it will report its 2007 fourth quarter and year-end financial results on Thursday, February 28, 2008, after market close. The company will host a live webcast at 4:30 p.m. EST that day to discuss these results.
The live webcast can be accessed at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1778268 (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your browser. Remove the space if one exists.) or via the Nabi Biopharmaceuticals website at http://www.nabi.com.
If you do not have Internet access, the U.S./Canada call-in number is 800-435-1261 and the international call-in number is 617-614-4076. The passcode is 84614235. An audio replay will be available for U.S./Canada callers at 888-286-8010 and for international callers at 617-801-6888. The replay passcode is 75615959.
The press release and an archived version of the webcast will be available on the company's website at http://www.nabi.com. The audio replay also will be available through March 6, 2008.
Annual Meeting of Shareholders
Nabi Biopharmaceuticals also announced today that its Annual Meeting of Shareholders will be held on Wednesday, May 7, 2008, at the Bethesda Marriott Hotel, 5151 Pooks Hill Road in Bethesda, Maryland, at 10:00 a.m. EDT (Phone: 301-897-9400).
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(r) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and StaphVAX(r) (Staphylococcus aureus Polysaccharide Conjugate Vaccine), a vaccine designed to prevent the most dangerous and prevalent strains of S. aureus bacterial infections. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit our Web site:http://www.nabi.com.